메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 15, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights Cash and bank balances were around RMB1,261 million as of June 30, 2025. Cash and cash equivalents and deposits at the end of 2025 are expected to be not less than RMB1,100 million. We expect to have adequate cash into the 2028 excluding subsequent cash inflows. During H1 2025, certification and regulatory filings for zevor-cel have been completed in more t
- 김갑성 기자
- 2025-08-15 08:15
TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future

BOSTON, Aug. 14, 2025 -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with its Orchestration Platform for Universal Solutions (OPUS). The new capabilities are designed to empower supply chain, finance, commercial, and IT leaders to master today's supply chain complexities and prepare for an agentic-first future. The platform and product releases—spanning OPUS, Multienterprise Information Network
- 김갑성 기자
- 2025-08-14 22:00
Sisram Medical will Report H1 2025 Financial Results on August 20 and Hold a Conference Call on August 21

[ 메디채널 김갑성 기자 ] H1 2025 conference call to be held on August 21, at 8:30 a.m. Eastern Time HONG KONG, Aug. 14, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including energy-based devices, injectables, and other complementary offerings, today announced that it expects to release its financial results for H1 2025, ended June 30
- 김갑성 기자
- 2025-08-14 20:00
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma

NANJING, China, Aug. 14, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody. This marks the world's first registrational clinical trial evaluating an immunotherapy monotherapy for extrapulmonary neuroendocrine carcinoma (EP-NEC). The study, led by Professor Shen Lin from Peking University Cancer Hospital and conduc
- 김갑성 기자
- 2025-08-14 17:38
Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden

[ 메디채널 김갑성 기자 ] Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with ease LONDON, Aug. 14, 2025 -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals navigate complex and evolving global requirements with greater ease, speed and confidence. Informed by customer i
- 김갑성 기자
- 2025-08-14 15:00
Medulla Expands Global Footprint with Strategic Launch in Singapore

SINGAPORE, Aug. 14, 2025 -- Medulla Communications Pvt. Ltd., one of the world's most awarded healthcare advertising agencies, has announced its expansion into Singapore, establishing a strategic hub to serve the Asia-Pacific region. Known for its expertise in solving healthcare challenges over 15 years, Medulla is looking to create a new super-specialist category as the first digital healthcare advertising agency in Asia. Medulla is one of the rare healthcare-specialist agencies to win the world's biggest awards for both creativity and marketing effectiveness, including Cannes
- 김갑성 기자
- 2025-08-14 13:30
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Aug. 14, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). Building on prior approvals in Singapore, Hong Kong SAR, and Macao SAR, as well as NDA acceptance
- 김갑성 기자
- 2025-08-14 12:02
Alpha Global partners with LIO to redefine Mental Health Care in Australia

New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers in Australia and New Zealand, today announced an exclusive distribution agreement for the newly launched LIO mental health operating platform. Jeremy Clare, Head of Product at Alpha Global, said: "We're incredibly excited to bring the second generation of mental health monitoring technology
- 김갑성 기자
- 2025-08-14 11:00
Alpha Global partners with LIO to redefine Mental Health Care in Australia

New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers in Australia and New Zealand, today announced an exclusive distribution agreement for the newly launched LIO mental health operating platform. Jeremy Clare, Head of Product at Alpha Global, said: "We're incredibly excited to bring the second generation of mental health monitoring technology
- 김갑성 기자
- 2025-08-14 11:00
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA delivers a novel dual-action mechanism, combining anti-inflammatory benefits with enhanced bile acid regulation. This innovative therapy promises to halt the progression of NAFLD to severe liver conditions such as NASH, cirrhosis,
- 김갑성 기자
- 2025-08-14 08:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 13시 00분